| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jeffrey M Cochran, Hui Fang, Christophe Le Gallo, Timothy Peters-Strickland, Jean-Pierre Lindenmayer, J Corey Reuteman-Fowle. Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. Patient preference and adherence vol 16 issue 2022 35923658 |
a recent, phase 3b, mirror-image clinical trial of outpatients with schizophrenia found that use of aripiprazole tablets with sensor (as; abilify mycite |
2022-08-04 |
2023-01-30 |
human |
| Dalia A Nawwar, Hala F Zaki, Rabab H Saye. Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology vol issue 2022 35876932 |
this study investigates the effects of aripiprazole and sertindole on the nrg1/erbb4 and pi3k/akt/mtor signaling pathways in ketamine-induced schizophrenia in rats. |
2022-07-25 |
2023-01-30 |
rat |
| David Fraguas, David Almenta Gallego, Sergio Arques-Egea, Marcos G\\xc3\\xb3mez-Revuelta, Carlos G\\xc3\\xb3mez S\\xc3\\xa1nchez-Lafuente, Daniel Hern\\xc3\\xa1ndez Huerta, Daniel N\\xc3\\xba\\xc3\\xb1ez Arias, Beatriz Oda Plasencia-Garc\\xc3\\xada, Carlos Parro Torres, Samuel Leopoldo Romero-Guillena, Elena Ros Cucurul, Cecilio Alam. Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International journal of psychiatry in clinical practice vol issue 2022 35792729 |
aripiprazole for the treatment of schizophrenia: recommendations of a panel of spanish experts on its use in clinical practice. |
2022-07-06 |
2023-01-27 |
Not clear |
| Taro Kishi, Kenji Sakuma, Nakao Iwat. Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis. Pharmacopsychiatry vol issue 2022 35790191 |
aripiprazole once-monthly versus oral aripiprazole for schizophrenia in the maintenance phase: a systematic review and network meta-analysis. |
2022-07-05 |
2023-01-27 |
Not clear |
| Taro Kishi, Kenji Sakuma, Nakao Iwat. Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis. Pharmacopsychiatry vol issue 2022 35790191 |
to examine whether aripiprazole once-monthly (aom) was more beneficial than oral aripiprazole (oari) in the treatment of adults with schizophrenia during the maintenance phase. |
2022-07-05 |
2023-01-27 |
Not clear |
| Guillaume Meyer, Clara Gitahy Falcao Faria, Marine Beck, Marielle Riutort, Bruno Michel, Herv\\xc3\\xa9 Javelo. Suicidality and psychotic episodes after starting aripiprazole: two case reports. International clinical psychopharmacology vol issue 2022 35695655 |
here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. |
2022-06-13 |
2023-01-27 |
Not clear |
| Jaedeok Kim, Nayoung Lee, Sang Bum Suh, Sooyeon Jang, Saeha Kim, Dong-Gyu Kim, Jong Kook Park, Keun-Wook Lee, Soo Young Choi, Chan Hee Le. Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance. BMB reports vol issue 2022 35651327 |
while atypical antipsychotics such as aripiprazole are not associated with obesity and diabetes, olanzapine is still widely used based on the anticipation that it is more effective in treating severe schizophrenia than aripiprazole, despite its metabolic side effects. |
2022-06-02 |
2023-01-27 |
mouse |
| Pierre-Michel Llorca, Philippe Nuss, \\xc3\\x89ric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, St\\xc3\\xa9phane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-No\\xc3\\xablle Vacheron, Jean-Michel Azori. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry vol 22 issue 1 2022 35643542 |
place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a delphi consensus study. |
2022-06-01 |
2023-01-27 |
Not clear |
| Pierre-Michel Llorca, Philippe Nuss, \\xc3\\x89ric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, St\\xc3\\xa9phane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-No\\xc3\\xablle Vacheron, Jean-Michel Azori. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry vol 22 issue 1 2022 35643542 |
aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. |
2022-06-01 |
2023-01-27 |
Not clear |
| Jaros\\xc5\\x82aw Sobi\\xc5\\x9b, \\xc5\\x81ukasz Kunert, Monika Rykaczewska-Czerwi\\xc5\\x84ska, El\\xc5\\xbcbieta \\xc5\\x9awi\\xc4\\x99tochowska, Piotr Gorczyc. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska vol 73 issue 1 2022 35381103 |
the effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. |
2022-04-05 |
2023-01-27 |
Not clear |
| Jaros\\xc5\\x82aw Sobi\\xc5\\x9b, \\xc5\\x81ukasz Kunert, Monika Rykaczewska-Czerwi\\xc5\\x84ska, El\\xc5\\xbcbieta \\xc5\\x9awi\\xc4\\x99tochowska, Piotr Gorczyc. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska vol 73 issue 1 2022 35381103 |
the aim of this study was to test the effect of aripiprazole on leptin, insulin, acute phase proteins, and selected cytokines levels in patients with chronic schizophrenia. |
2022-04-05 |
2023-01-27 |
Not clear |
| Mette \\xc3\\x98degaard Nielsen, Tina Dam Kristensen, Kirsten Borup Bojesen, Birte Y Glenth\\xc3\\xb8j, Cecilie K Lemvigh, Bj\\xc3\\xb8rn H Ebdru. Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses. Frontiers in psychiatry vol 13 issue 2022 35370857 |
aripiprazole is hypothesized to have an effect on negative and cognitive symptoms in schizophrenia. |
2022-04-04 |
2023-01-27 |
Not clear |
| Zofia Rog\\xc3\\xb3\\xc5\\xbc, Kinga Kami\\xc5\\x84ska, Marta Anna Lech, El\\xc5\\xbcbieta Lorenc-Koc. N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia. International journal of molecular sciences vol 23 issue 4 2022 35216241 |
n-acetylcysteine and aripiprazole improve social behavior and cognition and modulate brain bdnf levels in a rat model of schizophrenia. |
2022-02-26 |
2023-01-27 |
rat |
| Blanca Fern\\xc3\\xa1ndez-Abascal, Maria Recio-Barbero, Margarita S\\xc3\\xa1enz-Herrero, Rafael Segarr. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Therapeutic advances in psychopharmacology vol 11 issue 2022 35186259 |
long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. |
2022-02-21 |
2023-01-27 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports vol issue 2022 35182040 |
aripiprazole lai two-injection start in a 16 year-old adolescent with schizophrenia. |
2022-02-19 |
2023-01-27 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports vol issue 2022 35182040 |
aripiprazole long-acting injection (lai) is approved for the treatment of schizophrenia in adults. |
2022-02-19 |
2023-01-27 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports vol issue 2022 35182040 |
aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13- to 17-year-old adolescents with schizophrenia by the ema. |
2022-02-19 |
2023-01-27 |
Not clear |
| N V Baymeeva, I I Miroshnichenko, A I Platova, D V Tikhonov, V G Kaled. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol 122 issue 1 2022 35175709 |
[therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. |
2022-02-17 |
2023-01-27 |
Not clear |
| N V Baymeeva, I I Miroshnichenko, A I Platova, D V Tikhonov, V G Kaled. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol 122 issue 1 2022 35175709 |
to personalize pharmacotherapy with aripiprazole in patients with schizophrenia via therapeutic drug monitoring (tdm). |
2022-02-17 |
2023-01-27 |
Not clear |
| Pavel Mohr, Jir\\xc3\\xad Masopust, Miloslav Kope\\xc4\\x8de. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Frontiers in psychiatry vol 12 issue 2022 35145438 |
in two acute schizophrenia rcts of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. |
2022-02-11 |
2023-01-27 |
Not clear |